Abstract: Prognostic molecular markers identified in leukemia are becoming increasingly important especially in risk stratification and to determine therapy. In this study, we investigate the role of ELK-1 transcription factor and its potential target genes in four cell lines; Daudi, Jurkat, K-562 and HL-60. To evaluate ELK-1, MCPIP, MCL-1, BCL-10, CEBPB and SRF genes expression profiles we have performed a Real-time PCR analysis on Daudi, Jurkat, K-562 and HL-60 cell lines. ELK-1 over expression concomitant with SRF overexpression was detected only in Daudi cell line while only SRF overexpression was detected in jurkat cells. Expression of MCPIP, MCL-1, BCL-10 and CEBPB genes were decreased in all cell lines. Protein levels or phosphorylation status of ELK-1, BCL-10, CEBPB, MCL-1, MCPIP and SRF, moreover, changes that may occur when ELK-1 continuous overexpression is provided or completely silenced in these cell lines have not been evaluated. These questions are suggestions for future investigations. 
Introduction
Understanding the pathogenesis of and identification markers to diagnose leukemia is still the subject of many studies. Recurrent balanced structural rearrangements are very important in diagnosis and accepted as prognostic factors in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and other hematologic malignancies [1] . However, some imbalanced chromosomal abnormalities, especially submicroscopic rearrangements, cannot be detected by conventional cytogenetics [2] .
In our previous study, we have used oligo array Comparative Genomic Hybridization (oaCGH) to characterize chromosomal rearrangements in 41 acute leukemia samples. Along with many findings, one of the prominent one was the recurrent duplication of the ELK-1 oncogene which was observed in both ALL and AML cases. We have also reported deletion of CEBPB (CCAAT Enhancer Binding Protein-B) and duplication of serum response factor (SRF) in AML patients [3] .
ELK-1, along with ELK-4 (SAP1) and ELK-3 (SAP2/Net), is a member of the ternary complex factor (TCF) subfamily of ETS-domain transcription factors which do not exhibit tissue specificity [4] [5] [6] . Ternary complex factors, with respect to the serum response, activate transcription of immediate-early genes (IEG) such as c-fos, egr-1, and nur77, and the muscle-specific genes; actin, myosin heavy chain and muscle creatine kinase. ELK-1 regulation of these genes is mediated by serum response elements (SREs) that bind SRF, a transcription factor that belongs to the MADS box family [7, 8] and can be activated by mitogen-activated protein (MAP) kinase phosphorylation [9, 10] . An interruption in the MAPK signaling pathway has been reported by numerous studies in many cancer types including hematological malignancies [11, 12] .
In addition to immediate growth response function of ELK-1, many studies are suggesting different roles, and /or ELK-1 might target a distinct subset of genes function in many developmental processes, from hematopoiesis to formation of functional neural circuits [4, 13] . CEBPB is a group of transcription factors that belong to the CREB superfamily, participating in a number of biologic responses, including energy metabolism, fat storage, tissue differentiation, hematopoiesis, the immune response, antibacterial defense, and female fertility [14, 15] . The CEBPB is a candidate ELK-1-interacting protein through the MAPK pathway that also plays a role in the suppression of myeloid and lymphoid leukemogenesis [14, 15] .
As far as our knowledge is concerned, published data searching a role for ELK-1 in leukemia pathogenesis and /or prognosis are very limited. For this purpose, in this study we investigated whether there was a change in the expression of ELK-1, CEBPB and SRF genes. We have tried to answer these questions; Does ELK-1 gene amplification that we have detected using oaCGH, also means an increase in the mRNA transcription? If so, does ELK-1 increased expression affect SRF and CEBPB mRNA transcription on lymphoma-leukemia model cell lines? In this presented study, besides CEBPB and SRF small subset of possible candidate genes for ELK-1 transcription factor; MCPIP, Myeloid Cell Leukemia 1 (MCL-1) and B cell CLL/lymphoma 10 (BCL-10) genes expressions were evaluated.
MCPIP gene (also called the ZC3H12A gene), encodes MCPIP is an important regulator of inflammatory processes [16, 17] . MCPIP1 is induced by Monocyte Chemoattractant Protein-1 (MCP-1) and Interleukin (IL-1) whose signals are transduced through the Nuclear Factor Kappa B (NFkB) and MAPK pathways [17, 18] . The transcription factor ELK-1 plays an important role in the activation of MCPIP expression in response to IL-1b stimulation [19] . Previous studies have shown that as a response to cell differentiation and apoptosis-inducing stimuli of granulocyte / macrophage colony stimulating factor (GM-CSF) MCL-1 expression increases and induce cell differentiation HL-60, THP-1, U-937 and K562 cell lines [20] . A study by Boros, J. and colleagues found that the MCL-1 gene is associated with SRF and is one of the target genes of the ELK-1/SRF complex [5] . BCL-10 protein is an adaptor that activates the receptor-mediated apoptosis pathway and the NFkB survival pathway [21, 22] . The role of BCL-10 in acute leukemia is less clear. However, ELK-1 has been shown to suppress the BCL-10 promoter [4] for this reason BCL-10 as one of the possible candidate genes has been included to the study.
Material and Method

Control samples and cell lines
Viable cell suspensions were obtained from peripheral blood samples of 24 healthy volunteers and used as control samples. The human leukemia cell lines Daudi, Jurkat, K-562, and HL-60 were obtained from American Type Culture Collection (ATCC, USA)
Cell cultures
Jurkat, Daudi, K-562, HL-60 cell lines were maintained in RPMI1640 (Sigma) medium supplemented with 10% fetal calf serum (Multicell), 1% L-glutamine (Multicell), 1% penicillinstreptomycin (Sigma) and 1% amphotericin B (Multicell) in a humidified atmosphere with 5% CO2 at 37°C. Living cells were stained with trypan blue (Fluka) staining, and subsequent cells count was quantified with a Neubauer chamber (Marienfeld). RNA isolation was performed when the number of cells reached 5.3x10 6 cells/flask.
RNA isolation, reverse transcriptase-PCR, and real time-PCR studies
RNA isolation performed with PureLink RNA mini kit (Invitrogen) for cell lines and Miniblood RNA isolation kit (Qiagen) were used for blood samples. RNA from all samples was quantified by spectrometric analysis (Thermo Fisher Scientific Nanodrop products, DE, USA). cDNA was obtained using Applied High Capacity RT kit (Roche). 
Results
ELK-1, MCPIP, MCL-1, BCL-10, CEBPB and SRF genes expression were determined in Human leukemia cell lines Jurkat, K-562, HL-60 and lymphoma cell line Daudi. Relative Quantity (RQ) values were analyzed for each experimental group using 7500 Fast-SDS program. GAPDH was used as endogenous control and Control group accepted as reference sample (means that the expression of the gene of interest is 100% and so the RQ value is 1 [23] ).
Graphical demonstration of Real-time PCR results for the four cell lines included in the study are given in Figure 1 and RQ values obtained from control group and cell lines are given in Table 1 . Identification of different ELK-1 target genes aside from the IEG is a research topic for many studies. However, there are limited research exploring association between ELK-1 overexpression and haematological malignancies in the literature. We have performed our study in HL-60, Jurkat, Daudi and K-562 cell lines which are often used as a model for the investigation of hematological malignancies and determined the changes in gene expression of ELK-1. In addition, the expression levels of five genes (BCL-10, CEBPB, MCL-1, MCPIP and SRF) that are possible targets for ELK-1 were also investigated in order to elucidate the role of ELK-1 in leukemogenesis.
Discussion and Conclusion
ELK-1 is a member of ETS (E-twenty
Relative Quantification (RQ) was performed using the GAPDH as endogenous control and control group as a calibrator according to the average Ct values obtained. Fold difference in gene expression was calculated according to RQ values of GAPDH of the control group. In the Daudi cell line, the ELK-1 gene expression increased 2.03 fold and the SRF gene expression increased 1.50 fold. In the Jurkat cell line, only ELK-1 gene expression increased 1.20 fold (Table 1 ). There were no changes in the expression of ELK-1, SRF, MCPIP, MCL-1, BCL-10 or CEBPB genes in the other two cell lines. Both Daudi and Jurkat cells are lymphoblastic in the origin but, no change in ELK-1 expression was detected in myeloblastic K-562 and HL-60 cells. In Daudi cell line, an increase in the gene expression of SRF involved in the ternary complex with ELK-1 transcription factor was observed. In the Jurkat cell line, the SRF gene was not affected by the increase in ELK-1. The CEBP are a group of transcription factors that belong to the CREB superfamily, participating in a number of biologic responses, including energy metabolism, fat storage, tissue differentiation, hematopoiesis, the immune response, antibacterial defense, and female fertility [14, 15] . Studies have shown that CEBPB plays a critical role in acute promyelocytic leukemia cell differentiation. The CEBPB protein is a candidate ELK-1 interacting protein through the MAPK pathway that also plays a role in the suppression of myeloid and lymphoid leukemogenesis [14, 15] . However, in our study, it was determined that the expression of CEBPB did not change in Daudi and Jurkat cells, in which ELK-1 transcription was increased.
We haven't examined the changes in the protein levels or phosphorylation status of BCL-10, CEBPB, MCL-1, MCPIP and SRF. Moreover, changes that may occur when ELK-1 continuous overexpression is provided or completely silenced in these cell lines have not been evaluated. These questions are suggestions for future studies.
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